Compensation award — excluded from discretionary-purchase analysis.
Traded Feb 2, 2026 · Filed Feb 3, 2026
The boss of Boston Scientific sold $14.9M of Boston Scientific shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$14,930,526
Shares × reported transaction price
103 days after results of Oct 22, 2025, 2 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $91.87 on Feb 2, 2026, within 5% of its 52-week low, after a 3% drop over the previous 30 trading days
52-week range $88.07 (Jan 16, 2026) to $108.14 (Sep 8, 2025), 19% of the way up, from 251 adjusted closes. 30 trading days earlier: $94.48 on Dec 17, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.7% | +0.8% | -3.5% |
| 30 days | -5.5% | -2.0% | -3.5% |
| 90 days | -25.9% | +5.5% | -31.3% |
| 180 days | -35.9% | +10.4% | -46.3% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.